BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 14587293)

  • 1. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors.
    Nagase H; Brew K
    Biochem Soc Symp; 2003; (70):201-12. PubMed ID: 14587293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.
    Hosseini A; Kumar S; Hedin K; Raeeszadeh-Sarmazdeh M
    Protein Sci; 2023 Dec; 32(12):e4795. PubMed ID: 37807423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
    Wei S; Xie Z; Filenova E; Brew K
    Biochemistry; 2003 Oct; 42(42):12200-7. PubMed ID: 14567681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition.
    Lee MH; Rapti M; Knaüper V; Murphy G
    J Biol Chem; 2004 Apr; 279(17):17562-9. PubMed ID: 14734567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes.
    Batra J; Soares AS; Mehner C; Radisky ES
    PLoS One; 2013; 8(9):e75836. PubMed ID: 24073280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering of selective TIMPs.
    Nagase H; Meng Q; Malinovskii V; Huang W; Chung L; Bode W; Maskos K; Brew K
    Ann N Y Acad Sci; 1999 Jun; 878():1-11. PubMed ID: 10415716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMP-TIMP interaction depends on residue 2 in TIMP-4.
    Stratmann B; Farr M; Tschesche H
    FEBS Lett; 2001 Nov; 507(3):285-7. PubMed ID: 11696356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A).
    Troeberg L; Tanaka M; Wait R; Shi YE; Brew K; Nagase H
    Biochemistry; 2002 Dec; 41(50):15025-35. PubMed ID: 12475252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes.
    Muir EM; Adcock KH; Morgenstern DA; Clayton R; von Stillfried N; Rhodes K; Ellis C; Fawcett JW; Rogers JH
    Brain Res Mol Brain Res; 2002 Apr; 100(1-2):103-17. PubMed ID: 12008026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.
    Remacle AG; Shiryaev SA; Radichev IA; Rozanov DV; Stec B; Strongin AY
    J Biol Chem; 2011 Jun; 286(23):21002-12. PubMed ID: 21518756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme.
    Lee MH; Rapti M; Murphy G
    J Biol Chem; 2005 Apr; 280(16):15967-75. PubMed ID: 15713681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
    Gomis-Rüth FX; Maskos K; Betz M; Bergner A; Huber R; Suzuki K; Yoshida N; Nagase H; Brew K; Bourenkov GP; Bartunik H; Bode W
    Nature; 1997 Sep; 389(6646):77-81. PubMed ID: 9288970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase.
    Lee MH; Rapti M; Murphy G
    J Biol Chem; 2003 Oct; 278(41):40224-30. PubMed ID: 12869573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.
    Hamze AB; Wei S; Bahudhanapati H; Kota S; Acharya KR; Brew K
    Protein Sci; 2007 Sep; 16(9):1905-13. PubMed ID: 17660250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.
    Brew K; Nagase H
    Biochim Biophys Acta; 2010 Jan; 1803(1):55-71. PubMed ID: 20080133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into MMP-TIMP interactions.
    Bode W; Fernandez-Catalan C; Grams F; Gomis-Rüth FX; Nagase H; Tschesche H; Maskos K
    Ann N Y Acad Sci; 1999 Jun; 878():73-91. PubMed ID: 10415721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases.
    Huang W; Meng Q; Suzuki K; Nagase H; Brew K
    J Biol Chem; 1997 Aug; 272(35):22086-91. PubMed ID: 9268350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium.
    Goffin F; Munaut C; Frankenne F; Perrier D'Hauterive S; Béliard A; Fridman V; Nervo P; Colige A; Foidart JM
    Biol Reprod; 2003 Sep; 69(3):976-84. PubMed ID: 12773401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics.
    Nagase H; Brew K
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S51-61. PubMed ID: 12110123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.